APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody Sequencing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Monoclonal Antibody Sequencing Market Outlook and Growth Opportunities 2026

15 April 2026Not stated

Choose your research edition.

Industry ResearchMonoclonal Antibody Sequencing Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody Sequencing Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody Sequencing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody Sequencing Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody Sequencing Market Analysis and Forecast 2026-2032230 pages · $4,950 USD

Market perspective

The global Monoclonal Antibody Sequencing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Monoclonal Antibody Sequencing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Monoclonal Antibody Sequencing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monoclonal Antibody Sequencing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Monoclonal Antibody Sequencing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Monoclonal Antibody Sequencing market include Rapid Novor, GenScript, Labtoo, Helmholtz Munich, Molecular Cloning Laboratories, Syd Labs, Poochon, ProteoGenix and Creative Biolabs, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Monoclonal Antibody Sequencing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Monoclonal Antibody Sequencing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Monoclonal Antibody Sequencing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Monoclonal Antibody Sequencing market.

Monoclonal Antibody Sequencing Segment by Company

Rapid Novor

GenScript

Labtoo

Helmholtz Munich

Molecular Cloning Laboratories

Syd Labs

Poochon

ProteoGenix

Creative Biolabs

Monoclonal Antibody Sequencing Segment by Type

Protein Sequencing

Gene Sequencing

Monoclonal Antibody Sequencing Segment by Application

Clinical Trials

Antibody Discovery

Vaccine Development

Other

Monoclonal Antibody Sequencing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Monoclonal Antibody Sequencing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Monoclonal Antibody Sequencing key companies, revenue, market share, and recent developments.

3. To split the Monoclonal Antibody Sequencing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Monoclonal Antibody Sequencing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Monoclonal Antibody Sequencing significant trends, drivers, influence factors in global and regions.

6. To analyze Monoclonal Antibody Sequencing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody Sequencing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody Sequencing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody Sequencing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Monoclonal Antibody Sequencing industry.

Chapter 3: Detailed analysis of Monoclonal Antibody Sequencing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Monoclonal Antibody Sequencing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Monoclonal Antibody Sequencing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Monoclonal Antibody Sequencing Industry Trends Table 2. Monoclonal Antibody Sequencing Industry Drivers Table 3. Monoclonal Antibody Sequencing Industry Opportunities and Challenges Table 4. Monoclonal Antibody Sequencing Industry Restraints Table 5. Global Monoclonal Antibody Sequencing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Monoclonal Antibody Sequencing Revenue Share by Company (2021-2026) Table 7. Global Monoclonal Antibody Sequencing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Monoclonal Antibody Sequencing Key Company Manufacturing Base & Headquarters Table 9. Global Monoclonal Antibody Sequencing Company, Product Type & Application Table 10. Global Monoclonal Antibody Sequencing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Monoclonal Antibody Sequencing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Protein Sequencing Table 15. Significant Companies of Gene Sequencing Table 16. Global Monoclonal Antibody Sequencing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Monoclonal Antibody Sequencing Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Monoclonal Antibody Sequencing Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Monoclonal Antibody Sequencing Sales Value Share by Type (2021-2026) Table 20. Global Monoclonal Antibody Sequencing Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Clinical Trials Table 22. Significant Companies of Antibody Discovery Table 23. Significant Companies of Vaccine Development Table 24. Significant Companies of Other Table 25. Global Monoclonal Antibody Sequencing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Monoclonal Antibody Sequencing Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Monoclonal Antibody Sequencing Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Monoclonal Antibody Sequencing Sales Value Share by Application (2021-2026) Table 29. Global Monoclonal Antibody Sequencing Sales Value Share by Application (2027-2032) Table 30. Global Monoclonal Antibody Sequencing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Monoclonal Antibody Sequencing Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Monoclonal Antibody Sequencing Sales Value Share by Region (2021-2026) Table 33. Global Monoclonal Antibody Sequencing Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Monoclonal Antibody Sequencing Sales Value Share by Region (2027-2032) Table 35. Global Monoclonal Antibody Sequencing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Monoclonal Antibody Sequencing Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Monoclonal Antibody Sequencing Sales Value Market Share by Country (2021-2026) Table 38. Global Monoclonal Antibody Sequencing Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Monoclonal Antibody Sequencing Sales Value Market Share by Country (2027-2032) Table 40. Rapid Novor Company Information Table 41. Rapid Novor Business Overview Table 42. Rapid Novor Monoclonal Antibody Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Rapid Novor Monoclonal Antibody Sequencing Product Portfolio Table 44. Rapid Novor Recent Development Table 45. GenScript Company Information Table 46. GenScript Business Overview Table 47. GenScript Monoclonal Antibody Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. GenScript Monoclonal Antibody Sequencing Product Portfolio Table 49. GenScript Recent Development Table 50. Labtoo Company Information Table 51. Labtoo Business Overview Table 52. Labtoo Monoclonal Antibody Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Labtoo Monoclonal Antibody Sequencing Product Portfolio Table 54. Labtoo Recent Development Table 55. Helmholtz Munich Company Information Table 56. Helmholtz Munich Business Overview Table 57. Helmholtz Munich Monoclonal Antibody Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Helmholtz Munich Monoclonal Antibody Sequencing Product Portfolio Table 59. Helmholtz Munich Recent Development Table 60. Molecular Cloning Laboratories Company Information Table 61. Molecular Cloning Laboratories Business Overview Table 62. Molecular Cloning Laboratories Monoclonal Antibody Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Molecular Cloning Laboratories Monoclonal Antibody Sequencing Product Portfolio Table 64. Molecular Cloning Laboratories Recent Development Table 65. Syd Labs Company Information Table 66. Syd Labs Business Overview Table 67. Syd Labs Monoclonal Antibody Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Syd Labs Monoclonal Antibody Sequencing Product Portfolio Table 69. Syd Labs Recent Development Table 70. Poochon Company Information Table 71. Poochon Business Overview Table 72. Poochon Monoclonal Antibody Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Poochon Monoclonal Antibody Sequencing Product Portfolio Table 74. Poochon Recent Development Table 75. ProteoGenix Company Information Table 76. ProteoGenix Business Overview Table 77. ProteoGenix Monoclonal Antibody Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. ProteoGenix Monoclonal Antibody Sequencing Product Portfolio Table 79. ProteoGenix Recent Development Table 80. Creative Biolabs Company Information Table 81. Creative Biolabs Business Overview Table 82. Creative Biolabs Monoclonal Antibody Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Creative Biolabs Monoclonal Antibody Sequencing Product Portfolio Table 84. Creative Biolabs Recent Development Table 85. Research Programs/Design for This Report Table 86. Authors List of This Report Table 87. Secondary Sources Table 88. Primary Sources List of Figures Figure 1. Monoclonal Antibody Sequencing Product Image Figure 2. Global Monoclonal Antibody Sequencing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monoclonal Antibody Sequencing Market Size (2021-2032) & (US$ Million) Figure 4. Global Monoclonal Antibody Sequencing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Protein Sequencing Image Figure 8. Gene Sequencing Image Figure 9. Global Monoclonal Antibody Sequencing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Monoclonal Antibody Sequencing Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Monoclonal Antibody Sequencing Sales Value Share by Type (2021-2032) Figure 12. Clinical Trials Image Figure 13. Antibody Discovery Image Figure 14. Vaccine Development Image Figure 15. Other Image Figure 16. Global Monoclonal Antibody Sequencing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Monoclonal Antibody Sequencing Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Monoclonal Antibody Sequencing Sales Value Share by Application (2021-2032) Figure 19. Global Monoclonal Antibody Sequencing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Monoclonal Antibody Sequencing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Monoclonal Antibody Sequencing Sales Value (2021-2032) & (US$ Million) Figure 22. North America Monoclonal Antibody Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Monoclonal Antibody Sequencing Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Monoclonal Antibody Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Monoclonal Antibody Sequencing Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Monoclonal Antibody Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Monoclonal Antibody Sequencing Sales Value (2021-2032) & (US$ Million) Figure 28. South America Monoclonal Antibody Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Monoclonal Antibody Sequencing Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Monoclonal Antibody Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Protein Sequencing
  • Gene Sequencing
Applications
  • Clinical Trials
  • Antibody Discovery
  • Vaccine Development
  • Other
Companies covered
  • Rapid Novor
  • GenScript
  • Labtoo
  • Helmholtz Munich
  • Molecular Cloning Laboratories
  • Syd Labs
  • Poochon
  • ProteoGenix
  • Creative Biolabs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Monoclonal Antibody Sequencing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Monoclonal Antibody Sequencing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Monoclonal Antibody Sequencing Market Dynamics
  1. 2.1 Monoclonal Antibody Sequencing Industry Trends
  2. 2.2 Monoclonal Antibody Sequencing Industry Drivers
  3. 2.3 Monoclonal Antibody Sequencing Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibody Sequencing Industry Restraints
3 Monoclonal Antibody Sequencing Market by Company
  1. 3.1 Global Monoclonal Antibody Sequencing Company Revenue Ranking in 2025
  2. 3.2 Global Monoclonal Antibody Sequencing Revenue by Company (2021-2026)
  3. 3.3 Global Monoclonal Antibody Sequencing Company Ranking (2024-2026)
  4. 3.4 Global Monoclonal Antibody Sequencing Company Manufacturing Base and Headquarters
  5. 3.5 Global Monoclonal Antibody Sequencing Company Product Type and Application
  6. 3.6 Global Monoclonal Antibody Sequencing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Monoclonal Antibody Sequencing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Monoclonal Antibody Sequencing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Monoclonal Antibody Sequencing Market by Type
  1. 4.1 Monoclonal Antibody Sequencing Type Introduction
  2. 4.1.1 Protein Sequencing
  3. 4.1.2 Gene Sequencing
  4. 4.2 Global Monoclonal Antibody Sequencing Sales Value by Type
  5. 4.2.1 Global Monoclonal Antibody Sequencing Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Monoclonal Antibody Sequencing Sales Value by Type (2021-2032)
  7. 4.2.3 Global Monoclonal Antibody Sequencing Sales Value Share by Type (2021-2032)
5 Monoclonal Antibody Sequencing Market by Application
  1. 5.1 Monoclonal Antibody Sequencing Application Introduction
  2. 5.1.1 Clinical Trials
  3. 5.1.2 Antibody Discovery
  4. 5.1.3 Vaccine Development
  5. 5.1.4 Other
  6. 5.2 Global Monoclonal Antibody Sequencing Sales Value by Application
  7. 5.2.1 Global Monoclonal Antibody Sequencing Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Monoclonal Antibody Sequencing Sales Value by Application (2021-2032)
  9. 5.2.3 Global Monoclonal Antibody Sequencing Sales Value Share by Application (2021-2032)
6 Monoclonal Antibody Sequencing Regional Value Analysis
  1. 6.1 Global Monoclonal Antibody Sequencing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Monoclonal Antibody Sequencing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Monoclonal Antibody Sequencing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Monoclonal Antibody Sequencing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Monoclonal Antibody Sequencing Sales Value (2021-2032)
  7. 6.3.2 North America Monoclonal Antibody Sequencing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Monoclonal Antibody Sequencing Sales Value (2021-2032)
  10. 6.4.2 Europe Monoclonal Antibody Sequencing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Monoclonal Antibody Sequencing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Monoclonal Antibody Sequencing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Monoclonal Antibody Sequencing Sales Value (2021-2032)
  16. 6.6.2 South America Monoclonal Antibody Sequencing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Monoclonal Antibody Sequencing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Monoclonal Antibody Sequencing Sales Value Share by Country, 2025 VS 2032
7 Monoclonal Antibody Sequencing Country-level Value Analysis
  1. 7.1 Global Monoclonal Antibody Sequencing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Monoclonal Antibody Sequencing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Monoclonal Antibody Sequencing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Monoclonal Antibody Sequencing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Monoclonal Antibody Sequencing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Monoclonal Antibody Sequencing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Monoclonal Antibody Sequencing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Rapid Novor
  2. 8.1.1 Rapid Novor Company Information
  3. 8.1.2 Rapid Novor Business Overview
  4. 8.1.3 Rapid Novor Monoclonal Antibody Sequencing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Rapid Novor Monoclonal Antibody Sequencing Product Portfolio
  6. 8.1.5 Rapid Novor Recent Developments
  7. 8.2 GenScript
  8. 8.2.1 GenScript Company Information
  9. 8.2.2 GenScript Business Overview
  10. 8.2.3 GenScript Monoclonal Antibody Sequencing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GenScript Monoclonal Antibody Sequencing Product Portfolio
  12. 8.2.5 GenScript Recent Developments
  13. 8.3 Labtoo
  14. 8.3.1 Labtoo Company Information
  15. 8.3.2 Labtoo Business Overview
  16. 8.3.3 Labtoo Monoclonal Antibody Sequencing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Labtoo Monoclonal Antibody Sequencing Product Portfolio
  18. 8.3.5 Labtoo Recent Developments
  19. 8.4 Helmholtz Munich
  20. 8.4.1 Helmholtz Munich Company Information
  21. 8.4.2 Helmholtz Munich Business Overview
  22. 8.4.3 Helmholtz Munich Monoclonal Antibody Sequencing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Helmholtz Munich Monoclonal Antibody Sequencing Product Portfolio
  24. 8.4.5 Helmholtz Munich Recent Developments
  25. 8.5 Molecular Cloning Laboratories
  26. 8.5.1 Molecular Cloning Laboratories Company Information
  27. 8.5.2 Molecular Cloning Laboratories Business Overview
  28. 8.5.3 Molecular Cloning Laboratories Monoclonal Antibody Sequencing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Molecular Cloning Laboratories Monoclonal Antibody Sequencing Product Portfolio
  30. 8.5.5 Molecular Cloning Laboratories Recent Developments
  31. 8.6 Syd Labs
  32. 8.6.1 Syd Labs Company Information
  33. 8.6.2 Syd Labs Business Overview
  34. 8.6.3 Syd Labs Monoclonal Antibody Sequencing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Syd Labs Monoclonal Antibody Sequencing Product Portfolio
  36. 8.6.5 Syd Labs Recent Developments
  37. 8.7 Poochon
  38. 8.7.1 Poochon Company Information
  39. 8.7.2 Poochon Business Overview
  40. 8.7.3 Poochon Monoclonal Antibody Sequencing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Poochon Monoclonal Antibody Sequencing Product Portfolio
  42. 8.7.5 Poochon Recent Developments
  43. 8.8 ProteoGenix
  44. 8.8.1 ProteoGenix Company Information
  45. 8.8.2 ProteoGenix Business Overview
  46. 8.8.3 ProteoGenix Monoclonal Antibody Sequencing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ProteoGenix Monoclonal Antibody Sequencing Product Portfolio
  48. 8.8.5 ProteoGenix Recent Developments
  49. 8.9 Creative Biolabs
  50. 8.9.1 Creative Biolabs Company Information
  51. 8.9.2 Creative Biolabs Business Overview
  52. 8.9.3 Creative Biolabs Monoclonal Antibody Sequencing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Creative Biolabs Monoclonal Antibody Sequencing Product Portfolio
  54. 8.9.5 Creative Biolabs Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst